Singapore's government has told the Life Insurance Association to explore moving critical illness definitions away from specific surgical procedures and toward underlying disease and severity. It is an important policy direction - and it changes nothing for the hundreds of thousands of policyholders already holding CI plans written under older frameworks.
Consider what the problem looks like in practice. A cardiologist today may recommend a transcatheter aortic valve implantation rather than open-heart surgery for a heart valve condition. A policyholder on a legacy CI plan that specifies the open-heart procedure as the claim trigger has a problem. The disease is the same. The severity is the same. The treatment is better. But the policy, written around the surgical approach that was standard when it was sold, may not respond. That is what the government is asking the LIA to fix for future products. It is not what it is fixing for existing ones.
Deputy Prime Minister and MAS Chairman Gan Kim Yong confirmed the direction in a written parliamentary reply on October 7, responding to West Coast-Jurong West GRC MP Dr Hamid Razak, who asked whether MAS would engage the LIA on ensuring clients do not lose cover solely because they received a newer, less invasive treatment not listed in their legacy policy wording. The LIA will explore whether definitions for certain medical conditions and diseases can place less reliance on specified procedures, and more on the underlying disease and its severity, in its next review commencing in 2027, according to The Online Citizen's reporting of the parliamentary reply.
Gan acknowledged that some CI plans use treatment procedures as objective indicators of disease severity and consequent financial impact - a design choice made because such plans pay a lump sum based on illness severity, not treatment costs. Any changes will require careful consideration as they affect the scope of coverage and claims experience, and premiums may also be affected, he said. Updated definitions will apply to new products sold.
As IBA Asia reported in August 2026 [link to previous IBA coverage], existing policyholders remain on the definitions in force when they purchased their policy. The LIA's periodic reviews apply only to new business going forward. A policyholder on an older CI plan gets none of the newer definitions, none of the multi-stage payout structure, and none of the recovery-period benefits unless an adviser initiates the review and walks them through whether to supplement or replace what they hold.
The LIA CI Framework 2024, published in June 2024 and mandatorily effective for all new policies from 1 October 2025, updated seven of the 37 standardised severe-stage critical illness definitions - revising Major Cancer, Coma, Deafness, Open-Heart Heart Valve Surgery, Terminal Illness, Persistent Vegetative State, and Other Serious Coronary Artery Disease, according to the LIA's published framework document. Clients holding policies issued before October 2025 are on the 2019 framework or earlier. Those holding policies issued before the 2019 review are on the framework before that. The gap between the oldest policies in force and the current clinical environment is not one update wide - it is several.
Over 90% of CI claims in Singapore are for major cancers, heart attacks of specified severity, and coronary artery bypass surgery, according to Singapore Finance's analysis of Singapore CI claims data. Those are precisely the conditions where treatment innovation is moving fastest and where the gap between a legacy procedure-anchored definition and the current standard of care is most likely to matter at claim time.
The parliamentary reply just gave advisers a new way to start an uncomfortable conversation The October 7 announcement does something important for financial advisers and insurance brokers even if it does not fix the legacy policyholder problem: it legitimises the review conversation in terms that clients will understand.
For years, advisers have faced the challenge of explaining why a policy a client has been paying premiums on for a decade might not respond to the treatment their oncologist or cardiologist recommends. That conversation has historically been difficult because it sounds like the adviser is finding fault with the client's existing cover. It is now a conversation the government has publicly endorsed as necessary - and one the LIA has been asked to address structurally.
The 2027 LIA review will take time. New products incorporating disease-severity definitions will take longer to reach scale. In the meantime, the gap between the definitions on older CI plans and the current clinical environment is not closing - it is widening, as medical innovation continues to move faster than any periodic review cycle can track.
For advisers with clients holding CI plans issued before October 2025, the October 7 announcement is the prompt to initiate a portfolio review, not a reason to wait for the 2027 outcome. The policy your client holds today is the one that will respond when they need it. Or not.
